Role of Memantine
Question 2: For people with dementia, does memantine, when compared to placebo/comparator, produce benefits/harm in the specified outcomes in non-specialist health settings?
Memantine should not be considered routinely for people with dementia in non-specialist health settings in low and middle income countries. Strength of recommendation: STANDARD
Memantine may be considered only when diagnosis of moderate to severe Alzheimer's Disease has been made, with adequate support and supervision by specialist. Consideration should be given to adherence and monitoring of adverse effects, which generally requires the availability of a carer. Baseline structured cognitive and functional assessment should be carried out. Follow up should be carried out on regular basis at least 3 monthly and treatment needs to be terminated in case of non-response. Strength of recommendation: STANDARD